Dr. Bianchi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Francis St
Boston, MA 02115Phone+1 617-732-5190Fax+1 617-732-5706
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2012 - 2016
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2009 - 2012
Universita San RaffaeleClass of 2006
Certifications & Licensure
MA State Medical License 2012 - 2025
MN State Medical License 2011 - 2012
Publications & Presentations
PubMed
- 189 citationsThe proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibitionGiada Bianchi, Laura Oliva, Paolo Cascio, Niccolò Pengo, Francesca Fontana
Blood. 2009-03-26 - 37 citationsAL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies: JACC: CardioOncology State-of-the-Art ReviewGiada Bianchi, Yifei Zhang, Raymond L. Comenzo
JACC. Cardiooncology. 2021-10-01 - 63 citationsPivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitorsSimone Cenci, Laura Oliva, Fulvia Cerruti, Enrico Milan, Giada Bianchi
Journal of Leukocyte Biology. 2012-11-01
Abstracts/Posters
- Targeting Myeloma Cell Metabolism Via Disruption of the Lnc-17-92 Transcriptional Program: Druggable New Vulnerability in Multiple MyelomaGiada Bianchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple MyelomaGiada Bianchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Loss-of-Function of Gabarap Impairs Bortezomib-Induced Anti-Tumor Immunity in Multiple Myeloma: Clinical ApplicationGiada Bianchi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
The Economic Effects of the Coronavirus May Kill More Americans Than the Virus ItselfJanuary 25th, 2021- Administered Earlier, Cilta-Cel CAR T Produces Deep, Durable Responses in Multiple Myeloma PatientsDecember 9th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
